Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dow Corning

This article was originally published in The Gray Sheet

Executive Summary

Completes leadership transition with appointment of President and CEO Richard Hazelton, 51, as chairman of the board "effective immediately." Hazelton replaces Keith McKennon, 60, who has served as chairman since February 1992 and is retiring. Hazelton will continue as CEO, a position he took over from McKennon in June 1993, but will relinquish the position of company president, which he has held since January 1993. Executive Vice President Gary Anderson, 49, becomes Dow Corning president. McKennon, a crisis management specialist, came to Dow Corning from Dow Chemical in February 1992, at the height of the silicone breast implant controversy ("The Gray Sheet" Feb. 17, 1992, p. 5)

You may also be interested in...

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.

Manpower Not Materials Could Hold German COVID-19 Testing Back

Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.

Commission Regulatory Advice For COVID-19 Medtech Sector Entrants Amid Counterfeit Concerns

A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts